ArticleScientific reports2025
Analysis of anticancer drug associated adverse reactions in depressive patients from vigibase.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Depressive symptomatology is prevalent among oncology patients and may influence the perception of adverse drug reactions (ADRs) to anticancer drugs. Understanding this relationship is crucial for optimizing treatment strategies and improving ADR management. This pharmacovigilance study analyzed VigiBase® data from 1968 (year of its establishment) to 2024. Focusing on reports involving antineoplastic or immunomodulating agents, a case/non-case disproportionality analysis was conducted to assess the reporting and seriousness of ADRs in patients receiving antidepressants. Multivariable analyses were performed for all ADRs and the most frequently reported ADRs. Reporting Odds Ratios (RORs) were considered significant if the 95% credible interval lower bound exceeded 1. Among 8,804,863 reports, 428,102 involved patients receiving antidepressants. Antidepressant use was associated with a higher likelihood of serious ADRs reporting(58%vs45%; adjusted-ROR:1.78, 95%CI:1.76–1.79). Increased reporting was observed for most tested ADRs, including fatigue(ROR:2.19, 95%CI:2.13–2.25), pain(ROR:2.79, 95%CI:2.69–2.89), and headache(ROR:2.56, 95%CI:2.46–2.62). The timing of antidepressant initiation did not significantly impact ADR reporting. Antidepressant use in oncology patients is associated with increased ADR reporting and seriousness, emphasizing the need for heightened clinical vigilance. Effective management of depressive symptomatology may improve ADR perception, treatment adherence, and patient well-being. Prospective studies are required to confirm these findings and inform targeted interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.